scanX
Marksans Pharma

Marksans Pharma

191.73
-1.34
(-0.69%)
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
Market Cap
8,690.90 Cr
EPS
8.40
PE Ratio
24.77
Dividend Yield
0.41 %
Industry
Healthcare
52 Week High
358.70
52 Week Low
162.00
PB Ratio
3.25
Debt to Equity
0.12
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Marksans Pharma Reports Strong Q2 Recovery with 16% Sequential Revenue GrowthToday
Marksans Pharma delivered robust quarterly results with revenue growing 16% sequentially to Rs. 720.4 crores, driven by improved demand across key markets and new product launches in digestive health and pain management. The company's EBITDA and PAT surged 44% and 70% quarter-on-quarter respectively, while its Unit 2 facility successfully completed US FDA inspection with zero observations, strengthening its compliance standards.
positive
Marksans Pharma Subsidiary Receives US FDA Approval for Anti-Diarrheal Medication2 days ago
Marksans Pharma Limited's wholly owned subsidiary Marksans Pharma Inc. received final US FDA approval for Loperamide Hydrochloride Tablets USP, 2mg (OTC), an anti-diarrheal medication. The approved product is bioequivalent to Kenvue Brands LLC's reference listed drug Imodium A-D Tablets, 2mg, expanding the company's generic pharmaceutical portfolio in the US market.
positive
Marksans Pharma's UK Subsidiary Receives MHRA Approval for Pain-Relief Tablets4 days ago
Marksans Pharma's UK subsidiary Relonchem Limited received MHRA authorization to market Mefenamic Acid Film-Coated Tablets in 250mg and 500mg strengths for pain relief. The approval expands the Mumbai-based company's UK generics market presence, with shares climbing to ₹198.99 following the announcement.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,779.70
#1 4,27,009.64
40.68
#1 54,729.00
9.71
#1 10,980
2.89
71.91
Divis Laboratories
6,373.00
1,69,183.13
69.05
9,712.00
18.67
2,191
35.10
42.53
Torrent Pharmaceuticals
3,686.50
1,24,767.91
58.80
11,539.40
6.99
1,911
30.46
50.58
Cipla
1,511.80
1,22,116.26
22.73
28,409.50
7.12
5,291
3.71
43.38
Dr Reddys Laboratories
1,243.90
1,03,817.61
#1 18.15
33,741.20
16.73
5,725
-0.38
51.48
Zydus Life Science
924.30
93,006.21
18.56
23,511.00
18.55
4,615
34.60
32.09
Lupin
2,029.40
92,693.76
21.34
22,909.50
13.74
3,306
#1 72.75
58.39
Mankind Pharma
2,242.10
92,544.58
52.05
12,744.20
#1 20.90
2,007
-21.05
33.57
Aurobindo Pharma
1,205.90
70,038.87
20.70
32,345.60
9.43
3,484
3.81
62.63
Alkem Laboratories
5,700.00
68,152.05
28.29
13,458.30
3.70
2,216
10.98
60.35

Automatic Screeners on ScanX

Community
Support 1 Breached
Growth Rate
Revenue Growth
20.89 %
Net Income Growth
21.50 %
Cash Flow Change
-10.31 %
ROE
1.79 %
ROCE
-1.58 %
EBITDA Margin (Avg.)
-2.67 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
171
210
256
217
210
187
187
215
192
221
274
219
199
239
268
249
257
247
264
288
335
331
360
355
336
355
370
375
433
450
467
498
497
510
550
591
577
606
642
710
724
626
742
Expenses
132
160
204
187
206
173
180
188
177
192
249
190
195
200
232
212
232
213
223
240
266
261
273
267
235
272
301
305
354
361
372
403
376
398
417
453
450
462
495
543
582
520
576
EBITDA
39
50
51
31
4
14
7
27
15
29
25
29
4
39
36
36
25
35
41
47
69
70
87
88
101
83
69
70
79
89
94
94
121
112
133
138
126
143
147
167
142
106
166
Operating Profit %
23 %
24 %
20 %
14 %
2 %
7 %
0 %
12 %
4 %
13 %
9 %
13 %
2 %
15 %
14 %
15 %
6 %
13 %
13 %
16 %
21 %
21 %
23 %
25 %
29 %
22 %
17 %
16 %
15 %
17 %
18 %
16 %
23 %
20 %
21 %
23 %
20 %
22 %
23 %
20 %
18 %
16 %
20 %
Depreciation
4
5
6
10
8
5
6
12
8
7
7
6
6
6
6
5
6
5
5
7
10
7
19
9
1
8
7
9
21
11
14
13
14
14
18
22
21
20
20
21
23
23
27
Interest
1
3
3
2
2
1
1
2
2
2
3
2
4
2
3
2
2
2
3
2
2
2
2
2
3
1
2
1
5
2
3
2
2
2
2
3
5
3
3
3
3
6
6
Profit Before Tax
36
45
43
19
0
7
-0
13
-1
20
15
21
-6
30
28
30
17
28
34
38
58
61
66
78
97
75
60
60
53
76
78
79
104
97
114
113
100
120
125
143
116
77
133
Tax
10
13
7
-0
4
2
-1
2
2
5
4
4
1
6
7
4
7
5
8
9
15
12
15
19
18
12
14
12
23
16
18
17
22
26
30
30
23
31
27
38
25
18
34
Net Profit
26
32
36
19
-4
5
1
12
-3
14
10
18
-7
25
21
25
10
23
26
30
43
49
51
59
80
63
46
48
30
60
60
62
83
70
84
83
78
89
98
105
91
58
99
EPS in ₹
0.61
0.77
0.85
0.44
-0.14
0.11
0.02
0.24
0.00
0.33
0.23
0.41
-0.17
0.58
0.48
0.60
0.21
0.52
0.63
0.71
1.00
1.20
1.21
1.42
1.93
1.51
1.11
1.20
0.69
1.46
1.52
1.56
1.97
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2.00
1.29
2.17
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
676
722
752
729
804
903
1,229
1,640
2,190
2,681
3,240
Fixed Assets
166
270
267
279
270
303
309
428
486
776
982
Current Assets
509
440
484
449
531
594
903
1,201
1,675
1,863
2,204
Capital Work in Progress
0
0
0
0
0
0
12
3
10
9
27
Investments
0
0
0
0
0
0
0
0
1
27
1
Other Assets
510
453
485
450
534
600
908
1,209
1,694
1,869
2,230
Total Liabilities
676
722
752
729
804
903
1,229
1,640
2,190
2,681
3,240
Current Liabilities
286
259
296
233
233
229
299
356
341
390
477
Non Current Liabilities
2
0
16
16
18
25
25
61
84
205
273
Total Equity
388
463
440
480
553
649
905
1,223
1,765
2,086
2,489
Reserve & Surplus
326
401
393
430
502
595
846
1,068
1,700
2,020
2,422
Share Capital
53
53
41
41
41
41
41
41
45
45
45
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
138
-150
-10
15
-7
60
119
94
176
21
93
Investing Activities
-33
-123
-21
-39
-14
-60
-45
-84
-259
-141
-49
Operating Activities
155
31
14
50
27
233
179
99
237
230
207
Financing Activities
17
-58
-4
3
-21
-114
-15
80
198
-69
-65
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Jan 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
48.25 %
48.25 %
48.25 %
48.25 %
48.25 %
48.25 %
48.60 %
49.00 %
43.80 %
43.85 %
43.85 %
43.85 %
43.85 %
43.85 %
43.87 %
43.87 %
43.87 %
43.87 %
43.87 %
43.87 %
FIIs
1.00 %
0.59 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.88 %
10.88 %
10.88 %
10.88 %
10.88 %
15.57 %
18.60 %
21.31 %
21.96 %
22.20 %
19.88 %
16.92 %
DIIs
0.09 %
0.34 %
0.34 %
0.34 %
0.46 %
0.95 %
0.95 %
0.96 %
0.87 %
1.46 %
3.65 %
3.15 %
3.82 %
5.17 %
3.75 %
4.10 %
4.30 %
4.56 %
5.50 %
5.28 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.15 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
41.50 %
41.71 %
42.41 %
42.47 %
41.36 %
40.77 %
39.76 %
39.69 %
35.19 %
34.42 %
32.36 %
32.12 %
30.80 %
30.91 %
29.47 %
26.77 %
26.24 %
25.77 %
26.75 %
29.53 %
Others
9.15 %
9.11 %
9.00 %
8.94 %
9.78 %
10.04 %
10.69 %
10.34 %
9.25 %
9.39 %
9.25 %
10.00 %
10.64 %
4.49 %
4.31 %
3.95 %
3.63 %
3.59 %
4.00 %
4.40 %
No of Share Holders
0
1,35,271
1,88,888
2,01,451
2,14,998
2,20,090
2,21,359
2,17,743
2,13,123
1,98,382
1,88,447
2,07,937
2,37,377
2,54,699
2,35,500
2,48,845
2,59,813
2,57,273
2,56,221
2,65,788

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.05 0.05 0.05 0.1 0.25 0.25 0.5 0.6 0.8
Dividend Yield (%) 0.00 0.16 0.2 0.36 0.2 0.55 0.34 0.33 0.27 0.41

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
17 Sept 2021 DIVIDEND Dividend
₹ 0.25 /share
 15 Sept 2021 73.95 71.05
23 Aug 2022 DIVIDEND Dividend
₹ 0.25 /share
 19 Aug 2022 46.70 50.80
07 Jun 2023 DIVIDEND Dividend
₹ 0.50 /share
 07 Jun 2023 75.73 89.51
17 Sept 2024 DIVIDEND Dividend
₹ 0.60 /share
 17 Sept 2024 169.55 293.85
24 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 24 Sept 2024 209.01 314.54
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Nov 2024 266.10 288.60
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Feb 2025 259.15 267.40
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 19 May 2025 225.54 241.40
01 Aug 2025 DIVIDEND Dividend
₹ 0.80 /share
 01 Aug 2025 241.40 227.80
08 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 08 Aug 2025 256.75 214.35
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Aug 2025 237.25 210.08
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 180.20 196.92

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome11 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Newspaper Publication Of Financial Results For The Quarter And Half Year Ended September 30 20254 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome7 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation8 days ago
Unaudited Financial Results For The Quarter And Half Year Ended 30 September 20258 days ago
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30 September 20258 days ago
Observance Of Vigilance Awareness Week 2025 At Marksans Pharma LimitedNov 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"Nov 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
ESG Score By CFC Finlease Private Limited (Voluntary)Oct 27, 2025
Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter And Nine Months Ended September 30 2025Oct 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 08, 2025
DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"Oct 06, 2025
Closure of Trading WindowSep 25, 2025
Grant Of ESOP Under Marksans Employees Stock Option Scheme 2024 (Scheme)Sep 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 22, 2025
DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"Sep 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 25, 2025
Saksham Niveshak 100 Days CampaignAug 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 25, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Results For The Quarter Ended June 30 2025Aug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today For Publication Of Financial ResultsAug 12, 2025
Voting Results For The 33Rd Annual General Meeting Of The Company.Aug 08, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2025
Re-Appointment Of Mr. Mark Saldanha For A Period Of 5 Years With Effect From 06-10-2025Jul 25, 2025
Addendum To The Notice Of 33Rd Annual General MeetingJul 25, 2025
Board Meeting Outcome for Outcome For Consideration And Re-Appointment Of Mr. Mark Saldanha Subject To The Approval Of The Shareholders At The Ensuing Annual General MeetingJul 25, 2025
Board Meeting Intimation for Consideration And Approval Of Financial Results For The Quarter Ended June 30 2025Jul 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Small Cap Fund Direct - Growth
0.93%
674950
0.28%
0.30%
UTI Multi Cap Fund Direct-Growth
1.27%
100000
0.12%
0.21%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.50%
8146
0.03%
0.03%
Groww Nifty Total Market Index Fund Direct - Growth
0.02%
27
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.29%
15
0.02%
0.03%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
-15
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
13
0.00%
0.00%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.02%
8
0.00%
0.00%
Samco Active Momentum Fund Direct - Growth
0.00%
0
0.00%
0.00%
TRUSTMF Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Motilal Oswal Quant Fund Direct-Growth
0.00%
0
0.00%
0.00%
Old Bridge Focused Fund Direct - Growth
0.00%
0
0.00%
0.00%
Kotak MNC Fund Direct-Growth
1.65%
0
0.14%
0.11%
Samco Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
TRUSTMF Flexi Cap Fund Direct - Growth
0.00%
0
0.00%
0.00%
Kotak Special Opportunities Fund Direct-Growth
2.48%
0
0.25%
0.22%
Unifi Flexi Cap Fund Direct-Growth
1.41%
0
0.05%
0.20%
UTI Aggressive Hybrid Fund Direct Fund-Growth
0.60%
0
0.04%
0.19%
UTI Healthcare Fund Direct-Growth
1.22%
0
0.09%
0.08%
UTI Large & Mid Cap Fund Direct-Growth
0.70%
0
0.03%
0.32%
Kotak Healthcare Fund Direct - Growth
1.89%
0
0.11%
0.30%
UTI Retirement Fund Direct
0.27%
0
0.00%
0.02%
UTI Retirement Fund Direct
0.27%
0
0.00%
0.02%
Bandhan Small Cap Fund Direct-Growth
0.35%
0
0.00%
-0.03%

Technical Indicators

RSI(14)
Neutral
58.13
ATR(14)
Less Volatile
6.68
STOCH(9,6)
Neutral
54.48
STOCH RSI(14)
Oversold
19.05
MACD(12,26)
Bullish
0.23
ADX(14)
Strong Trend
25.70
UO(9)
Bearish
43.70
ROC(12)
Uptrend And Accelerating
1.41
WillR(14)
Neutral
-38.28
Bearish
3
Neutral
2
Bullish
4
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104